DTU
DTU

A Diabetes Outcomes Progression Trial

Sponsor:GlaxoSmithKline

Reference number:NCT00279045

ADOPT was a pragmatic, real-life, double-blind, randomised multicentre study which was evaluating specifically whether thiazolidinediones, with their different mode of action, can provide more durable glycaemic control than metformin or sulphonylureas. By utilising a monotherapy approach, in people with T2DM diagnosed for less than three years who are antihyperglycaemic agent naïve, ADOPT was designed to compare the relative efficacy of these three oral agents as judged primarily by the time to monotherapy failure. ADOPT will provide data on the effect of mechanistically differing treatment options on metabolic control, beta cell function, and markers of macrovascular disease risk in type 2 diabetes.

Results

The ADOPT results were announced at the IDF 19th World Diabetes Congress in Cape Town on Monday 4th December at 16.30 local time and simultaneously published in the New England Journal of Medicine.

News

Rosiglitazone out-performs Metformin and Glyburide in terms of renal function as an early-stage type 2 diabetes treatment

19-Apr-2011
News Image

ADOPT (A Diabetes Outcomes Prevention Trial) showed that initial treatment with just rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. In CJASN, we examine the differences in albumin excretion, renal function and blood pressure over the course of 5 years between the treatment groups....

[Read more...]

More effective glycaemic control seen with rosiglitazone is explained by effects on both β-cell function and insulin sensitivity

22-Mar-2011
News Image

The ADOPT study (A Diabetes Outcomes Prevention Trial) showed that treatment with rosiglitazone alone provided somewhat more effective glycaemic control than metformin or glyburide alone, in patients with recently diagnosed type 2 diabetes. In a paper published recently in Diabetes, we examined changes in β-cell function and insulin sensitivity among the three treatments in ADOPT....

[Read more...]

Rosiglitazone Decreases C-Reactive Protein

09-Oct-2009
News Image

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial).
Steven E....

[Read more...]


[News archive]